Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04486222
Other study ID # 201910101RIND
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date November 23, 2020
Est. completion date December 21, 2022

Study information

Verified date May 2021
Source National Taiwan University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to evaluate the efficacy of accelerated bilateral repetitive transcranial magnetic stimulation (rTMS) on major depression, anxiety, cognitive function and physiological parameters in elderly depressive patients.


Description:

Repeated transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation treatment, showing good therapeutic effect to medicine treatment-refractory patients. Recent studies suggested bilateral DLPFC might be effective to geriatric depression. Accelerated treatment course was reported to have similar therapeutic effect and safety profile with traditional course. The investigators hypothesize accelerated bilateral rTMS is effective to geriatric depression and comorbid anxiety. Cognitive impairment and decreased parasympathetic tone are common in patients with major depression. The investigators hypothesize cognitive function and physiological indicators improve after accelerated bilateral rTMS. In this single-center, prospective double-blind, randomized, active-controlled trial, the investigators aim to recruit 100 patients older than 60 years, without neurocognitive disorders, and refractory to one or more antidepressants. The experimental group would receive an rTMS course with high-frequency stimulation at left DLPFC followed by low-frequency inhibition at right DLPFC, two sessions daily, five days a week, and two weeks in total. The standard treatment group would receive an rTMS course with high-frequency stimulation at left DLPFC as standard treatment parameters. Mood, cognition and physiological markers would be monitored every week. The primary outcome is response and remission rate of major depression measured by Hamilton Rating Scale for Depression.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date December 21, 2022
Est. primary completion date December 21, 2022
Accepts healthy volunteers No
Gender All
Age group 60 Years to 85 Years
Eligibility Inclusion Criteria: - age between 60-85 years - literate and received basic education for at least 2 years - diagnosis of major depressive disorder, without psychotic features, according to DSM-5 - have a score of 20 or greater on the 17-item Hamilton Depression Rating Scale - failed to achieve clinical response by at least 1 antidepressant trial of sufficient dosage for at least 4 weeks - psychoactive agents were in stable doses before randomization Exclusion Criteria: - active suicide plans or attempts; or suicide attempts in the last 12 months - diagnosis of schizophrenia or bipolar disorder according to DSM-5 - have DSM-5-confirmed substance use disorder (excluding tobacco) in the last 3 months - have delirium, major neurocognitive disorder or MMSE < 24 - current use of bupropion >300 mg/day, tricyclic antidepressant, clozapine, chlorpromazine, foscarnet, ganciclovir, ritonavir, theophylline or anti-epileptic agents excluding benzodiazepines - history of severe head trauma, epilepsy, multiple sclerosis, stroke, brain tumors, intracranial aneurysm, active intracranial infection, increased intracranial pressure, metallic implants in the brain, major brain surgery or major neurological diseases - with a cardiac pacemaker or defibrillator - received rTMS treatment before

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Repeated Transcranial Magnetic Stimulation
Magstim® Super Rapid² Transcranial Magnetic Stimulation System

Locations

Country Name City State
Taiwan Department of Psychiatry, National Taiwan University Hospital, Yun-Lin Branch Douliu

Sponsors (2)

Lead Sponsor Collaborator
National Taiwan University Hospital National Taiwan University Hospital, Yun-Lin Branch

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Degree of Change in 17-item Hamilton Depression Rating Scale (HAM-D 17) HAM-D 17 is a scale rating the severity of depression, covering emotional, cognitive and somatic symptoms of depression. Higher scores indicate higher severity. Response to treatment is defined as = 50% decrease in HAM-D 17; remission is defined as = 7 points in HAM-D 17. day 1, day 5, day 12, day 19
Secondary Degree of Change in Hamilton Anxiety Rating Scale (HAM-A) HAM-A is a scale rating the severity of anxiety, covering emotional, cognitive and somatic symptoms of anxiety. Higher scores indicate higher severity. day 1, day 5, day 12, day 19
Secondary Degree of Change in Mini-Mental State Examination (MMSE) MMSE is a wildly-used tool to evaluate several cognitive function domains. day 1, day 5, day 12, day 19
Secondary Degree of Change in Stroop Test Task 1 (word phase) requests a subject to say a color name string (red, green, blue) printed in black; Task 2 (color phase) requests a subject to say the printed colors (red, green, blue) of letter "x" string; Task 3 (interference phase) requests a subject to say the printed colors of a string of color names (red, green, blue). day 1, day 5, day 12, day 19
Secondary Degree of Change in Trail Making Test Task 1 requests a subject to connect a sequence of 25 consecutive numbers regardless of their colors; Task 2 requires a subject to connect 25 consecutive numbers in alternative colors. day 1, day 5, day 12, day 19
Secondary Degree of Change in Verbal Fluency Test This test requests a subject to speak as many names of vegetables, fishes or fruit as possible in 45 seconds. day 1, day 5, day 12, day 19
Secondary Degree of Change in Physiological Parameters ProComp5 Infiniti (SA7525) Biofeedback System would be used. Heart rate variability, skin conductance, body temperature and respiratory rate would be measured. day 1, day 5, day 12, day 19
See also
  Status Clinical Trial Phase
Recruiting NCT05915013 - Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response Phase 1
Completed NCT04469322 - Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression N/A
Recruiting NCT05415397 - Treating Immuno-metabolic Depression With Anti-inflammatory Drugs Phase 3
Recruiting NCT05988333 - Psychoeducational Intervention for Families With a Member Affected by Major Depression N/A
Completed NCT02919501 - Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder Phase 2
Completed NCT00976560 - Clinical Study to Test a New Drug to Treat Major Depression Phase 2
Recruiting NCT05518149 - A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) Phase 3
Not yet recruiting NCT06303076 - Tizanidine vs. Zolpidem in Primary Insomnia: A Randomized Trial Phase 4
Not yet recruiting NCT05901571 - Acupuncture and Escitalopram for Treating Major Depression Clinical Study N/A
Suspended NCT02546024 - Predictors of Treatment Response in Late-onset Major Depressive Disorder N/A
Completed NCT02452892 - Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD) N/A
Completed NCT01583400 - Enhanced Collaborative Depression Treatment in Primary Care: The RESPECT-D-E Trial N/A
Completed NCT01407575 - Buprenorphine for Treatment Resistant Depression Phase 3
Completed NCT01152996 - Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study Phase 3
Enrolling by invitation NCT00762866 - Psychiatric Genotype/Phenotype Project Repository
Completed NCT00366652 - Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects Phase 3
Completed NCT00384033 - Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder Phase 3
Completed NCT00369343 - Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women Phase 3
Completed NCT00316160 - Sexual Functioning Study With Antidepressants Phase 4
Completed NCT00149643 - Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence Phase 2